LEADER 01839oam 2200529 450 001 9910715152703321 005 20220307130757.0 035 $a(CKB)5470000002508487 035 $a(OCoLC)1227101459$z(OCoLC)1231540537 035 $a(EXLCZ)995470000002508487 100 $a20201217d2020 ua 0 101 0 $aeng 135 $aurbn||||a|||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNational Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020 $ereport (to accompany H.R. 4866) 210 1$a[Washington, D.C.] :$c[U.S. Government Publishing Office],$d[2020] 215 $a1 online resource (16 pages) 225 1 $aReport / 116th Congress, 2d session, House of Representatives ;$v116-513 300 $a"September 17, 2020." 320 $aIncludes bibliographical references. 517 $aNational Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020 606 $aPharmaceutical technology$zUnited States 606 $aPharmaceutical industry$zUnited States 606 $aPharmaceutical industry$2fast 606 $aPharmaceutical technology$2fast 607 $aUnited States$2fast 608 $aLegislative materials.$2fast 608 $aLegislative materials.$2lcgft 615 0$aPharmaceutical technology 615 0$aPharmaceutical industry 615 7$aPharmaceutical industry. 615 7$aPharmaceutical technology. 676 $a1.1/8:116-513 801 0$bGPO 801 1$bGPO 801 2$bGPO 801 2$bOCLCO 801 2$bOCLCF 801 2$bDWP 801 2$bOCLCQ 801 2$bGPO 906 $aBOOK 912 $a9910715152703321 996 $aNational Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020$93542270 997 $aUNINA